Role of CXCR2 Ligands/CXCR2 Biological Axis in Pancreatic Cancer
NCT ID: NCT00851955
Last Updated: 2016-01-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
150 participants
OBSERVATIONAL
2007-05-31
2011-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Systematic Hereditary Pancreatic Cancer Risk Assessment and Implications for Personalized Therapy
NCT03060720
Pancreatic Intraepithelial Neoplasia (PanIN) and the Association With Recurrence of Pancreatic Adenocarcinoma
NCT01219829
Minimally Invasive Detection of Lymphatic Micrometastases in Pancreatic Cancer
NCT00826982
Interrogation of Exosome-mediated Intercellular Signaling in Patients With Pancreatic Cancer
NCT02393703
A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer
NCT05604560
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1. Normal pancreas patients
Patients with no documented clinical history of pancreatic diseases supported by at least 1 negative imaging test (EUS, CT scan or MRI).
No interventions assigned to this group
2. Chronic pancreatitis patients
Patients with documented diagnosis of moderate to advanced chronic pancreatitis supported by at least 1 positive imaging test (EUS,CT scan or MRI).
No interventions assigned to this group
3. Pancreatic cancer patients
Patients with documented tissue diagnosis (or clinical suspicion) of Pancreatic Cancer.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Chronic pancreatitis - Documented diagnosis of moderate to advanced chronic supported bpancreatitisy at least 1 positive imaging test. (EUS, Ct scan or MRI)
* Pancreatic Cancer - Documented tissue diagnosis (or clinical suspicion) of Pancreatic Cancer.
18 Years
90 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mayo Clinic
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Massimo Raimondo, M.D.
PI
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Massimo Raimondo, MD
Role: PRINCIPAL_INVESTIGATOR
Mayo Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mayo Clinic
Jacksonville, Florida, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
07-000099
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.